Azathioprine in inflammatory bowel disease, a safe alternative?

ISSN： 1466-1861

Source： Mediators of Inflammation, Vol.7, Iss.3, 1998-06, pp. : 141-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta‐analysis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 10, 2013-11 ,pp. : 1255-1266

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

By Pasternak Björn Svanström Henrik Schmiegelow Kjeld Jess Tine Hviid Anders

American Journal of Epidemiology, Vol. 177, Iss. 11, 2013-06 ,pp. : 1296-1305

Oxford University Press

Access to resources Recommend Favorite

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 11, 2015-11 ,pp. : 1591-1595

John Wiley & Sons Inc

Access to resources Recommend Favorite

HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 615-620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 753-762

John Wiley & Sons Inc

Access to resources Recommend Favorite